3%~14% Glycosylated Hemoglobin Detection Reagen (HbA1c) Performance Index
Overview of HbA1c
Glycated hemoglobin (HbA1c) is the product of the combination of hemoglobin in the red blood cells of the human blood and the sugars in the serum. The combination of blood sugar and hemoglobin to produce glycated hemoglobin is an irreversible reaction. The occurrence of this reaction is directly proportional to the blood sugar concentration and can be maintained for about 120 days. Therefore, the glycosylated hemoglobin test can reflect the patient's blood glucose control in the past 8 to 12 weeks.
HbA1c Performance Index
| Detection range | sample size | Sample type | Test time |
| 3％~14％ | 10μl | Whole Blood | 15min |
Clinical significance of HbA1c
- Early screening and diagnosis of diabetes
- Effect evaluation of blood sugar control program
- Prediction of chronic complications of diabetes
- Distinguishing Stress Hyperglycemia and Diabetes
- Diagnosis and treatment monitoring of gestational diabetes (GDM), etc.
| Glycated hemoglobin control objectives | Adapt to the crowd |
| <6% | ①Newly diagnosed, young, without complications and concomitant diseases, and no adverse effects such as hypoglycemia and weight gain in hypoglycemic treatment; ②Those who do not need hypoglycemic intervention; ③Diabetes complicated with pregnancy; ④Diabetes discovered during pregnancy |
| <6.5% | ①<65 years old, no diabetic complications and serious concomitant diseases; ②Planned gestational diabetes patients |
| <7% | ①Patients younger than 65 years old who use insulin therapy; ②Patients ≥65 years old, no risk of hypoglycemia, good organ function, and survival time >15 years; ③Patients with planned gestational diabetes who receive insulin therapy |
| ≤7.5% | People with existing or very high risk of cardiovascular disease |
| <8% | ≥65 years old, expected survival period is 5-15 years |
| <9% | ①≥65 years of age or suffering from malignant tumors, expected survival time <5 years; ②Patients at high risk of hypoglycemia; ③Difficulties in implementing the treatment plan, such as mental or intellectual or visual impairment, poor medical conditions, etc. |
Application Department
Cardiology, laboratory, emergency, ICU, oncology, Nephrology,Pediatrics, endocrinology, gynecology, geriatrics, respiratory, thoracic surgery,Gastroenterology, Urology, etc
Clinical comparison of HbA1c
Company profile
Zhongxiu Science And Technology Co.,Ltd., is a high-tech enterprise engaged in the research and development, production and operation of in vitro diagnostic products. The in vitro diagnostic products developed by the company cover POCT series, microbial series, biochemical series and immune series reagents and supporting instruments.
The company has always adhered to the core concept of "fast and accurate, living up to life", committed to providing society with excellent products and services, and contributing to the cause of human health.
